Gain an Insight in to the European Central Nervous System Therapeutics Markets.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50528) has announced the addition of the new Frost & Sullivan Report "European Central Nervous System (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) Therapeutics Markets" to their offering. This Frost & Sullivan research service titled "European Central Nervous System (CNS) Therapeutics Markets" provides a detailed analysis of various neurological and psychiatric disorders. It provides a qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. of key drivers, restraints and trends, as well as detailed market forecasts of individual disorder segments and country-wise trends. It also consists of strategic recommendations to market participants to gain an advantage in the highly competitive market. In this research, Frost & Sullivan expert analysts thoroughly examine the following markets: anti-Alzheimer drugs, anti-Parkinsonian drugs, antiepileptics, pain management drugs, antidepressants Antidepressants Medications prescribed to relieve major depression. Classes of antidepressants include selective serotonin reuptake inhibitors (fluoxetine/Prozac, sertraline/Zoloft), tricyclics (amitriptyline/ Elavil), MAOIs (phenelzine/Nardil), and heterocyclics , and antipsychotics Antipsychotics A class of drugs used to control psychotic symptoms in patients with psychotic disorders such as schizophrenia and delusional disorder. Antipsychotics include risperidone (Risperdal), haloperidol (Haldol), and chlorpromazine (Thorazine). . Market Overview Increasing Ageing Population to Result in Greater Incidence of CNS Disorders The prevalence of central nervous system (CNS) disorders in the European population, which represents a significant component of overall healthcare expenses, is exhibiting a steady rise. Further, improving diagnostic techniques and growing awareness of these disorders are likely to result in an enhanced focus on the CNS therapeutics market. The ageing population is also expected to support market growth, as age is likely to be the most significant non-genetic risk factor contributing to most CNS disorders. In addition, the present lack of drugs to cater to the increasing number of patients diagnosed with CNS disorders offers tremendous scope to support new blockbuster products. The market for psychiatric disorders features a high level of competition, thereby resulting in a shift in focus to neurological disorders, states the analyst of this research service. Accordingly, overall market growth will rely on the performance of segments such as Alzheimer disease and multiple sclerosis. While no effective long-term treatment exists for diseases such as Alzheimer's and Parkinson's, the antipsychotics market also features a large proportion of patients hampered by side effects Side effects Effects of a proposed project on other parts of the firm. of drugs. Hence, the high level of unmet clinical needs effectively offers tremendous potential for the development of the CNS therapeutics market as a whole. Improved Focus on Product Life-cycle Management to Assist in Market Expansion In keeping with escalating healthcare costs, nations across Europe are implementing strategies to curtail overall costs, thus affecting the profit margins of pharmaceutical companies. Moreover, market penetration will prove difficult due to factors such as generic substitution, parallel reimportation re·im·port tr.v. re·im·port·ed, re·im·port·ing, re·im·ports To bring back into a country (goods made from its exported raw materials). re·im and reference pricing. The National Institute of Clinical Excellence (NICE) guidelines for multiple sclerosis and oral neuroleptics Neuroleptics Any of a class of drugs used to treat psychotic conditions. Mentioned in: Stuttering, Tardive Dyskinesia in the United Kingdom and the decentralisation n. 1. same as decentralization. Noun 1. decentralisation - the spread of power away from the center to local branches or governments decentralization spreading, spread - act of extending over a wider scope or expanse of space or time of reimbursement policies in Italy are certain decisions that are likely to have significant ramifications ramifications npl → Auswirkungen pl on the market, remarks the analyst. Product life-cycle management will become essential, particularly in the context of mature markets such as depression and psychosis. At the same time, research should focus on expanding product indications as well as sustaining the market shares of blockbuster molecules. In addition, focusing on emerging lifestyle-related CNS disorders such as smoking cessation smoking cessation Public health Temporary or permanent halting of habitual cigarette smoking; withdrawal therapies–eg, hypnosis, psychotherapy, group counseling, exposing smokers to Pts with terminal lung CA and nicotine chewing gum are often ineffective. , pre-menstrual depressive disorder (PMDD PMDD abbr. premenstrual dysphoric disorder Premenstrual dysphoric disorder (PMDD) Premenstrual syndrome (PMS); symptoms including back and abdominal pain, nervousness and irritability, headache, and breast tenderness ) and erectile dysfunction is expected to favourably impact market expansion. Moreover, marketing collaborations and consolidation through mergers and acquisitions will aid in offsetting the risks of drug development. Market participants would also do well to concentrate on novel drug delivery methods to exploit existing opportunities for market growth. For more information, visit http://www.researchandmarkets.com/reports/c50528 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion